Tocqueville Asset Management L.P. Trims Stake in Johnson & Johnson $JNJ

Tocqueville Asset Management L.P. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 258,233 shares of the company’s stock after selling 15,023 shares during the period. Johnson & Johnson accounts for 0.9% of Tocqueville Asset Management L.P.’s investment portfolio, making the stock its 28th biggest position. Tocqueville Asset Management L.P.’s holdings in Johnson & Johnson were worth $65,583,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in JNJ. World Investment Advisors raised its holdings in Johnson & Johnson by 19.6% in the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after acquiring an additional 26,450 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Johnson & Johnson by 0.8% in the fourth quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after purchasing an additional 28,370 shares during the period. Signal Advisors Wealth LLC increased its stake in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after purchasing an additional 6,539 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in Johnson & Johnson in the first quarter valued at $30,017,000. Finally, Brighton Jones LLC boosted its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on JNJ shares. Bank of America upped their price objective on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. Guggenheim boosted their target price on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Johnson Rice reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Finally, TD Cowen upped their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $268.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson continues to attract attention as a defensive, income-oriented healthcare holding. Commentary highlights the company’s history of maintaining and increasing dividends through recessions, which may support demand from long-term and retirement-focused investors. Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
• Positive Sentiment: An article reviewing J&J’s investments in 15 biotech and medtech companies points to potential strategic value and future upside from its investment portfolio, although these holdings are not currently a major earnings driver. Johnson & Johnson Owns Stakes in 15 Stocks. Here’s the Best of the Bunch.
• Neutral Sentiment: J&J will hold a conference call on October 13 to discuss third-quarter results. Chief Executive Officer Joaquin Duato, Chief Financial Officer Joseph Wolk, and other executives will participate. The event could provide a catalyst through updated guidance, pharmaceutical sales trends, and management commentary, but it does not change current fundamentals. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
• Neutral Sentiment: Recent commentary compares JNJ’s performance with the consumer-staples sector and highlights its exposure to artificial-intelligence-related investments. These themes may improve investor visibility, but neither represents a new company announcement or near-term earnings catalyst. Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

Johnson & Johnson Price Performance

JNJ opened at $265.79 on Tuesday. Johnson & Johnson has a twelve month low of $173.33 and a twelve month high of $276.47. The firm has a market cap of $640.53 billion, a price-to-earnings ratio of 30.80, a PEG ratio of 2.56 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a fifty day simple moving average of $259.57 and a 200 day simple moving average of $244.17.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts expect that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 63,972 shares of company stock worth $16,245,605 in the last quarter. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.